Photo taken from Guilherme Nader Marta/LinkedIn
Mar 22, 2024, 16:49
Guilherme Nader Marta: CLEOPATRA trial analysis shows that complete response at first imaging re-evaluation correlates with longer PFS and OS
Guilherme Nader Marta, Oncology Fellow at Jules Bordet Institute, shared on LinkedIn:
“Many patients with HER2-positive breast cancer have long-term response to trastuzumab-pertuzumab that is >16% with no evidence of progression at 8 years in the CLEOPATRA trial
In this analysis led by Véronique Debien we show that complete response at first imaging re-evaluation correlates with longer PFS and OS.”
Source: Guilherme Nader Marta/LinkedIn
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Dec 21, 2024, 22:40
Dec 21, 2024, 22:37
Dec 21, 2024, 22:26
Dec 21, 2024, 19:39
Dec 21, 2024, 19:21
Dec 21, 2024, 19:19